---
title: "Hepion Pharmaceuticals, Inc. (HEPA.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/HEPA.US.md"
symbol: "HEPA.US"
name: "Hepion Pharmaceuticals, Inc."
industry: "Pharmaceuticals"
datetime: "2026-04-15T12:41:50.977Z"
locales:
  - [en](https://longbridge.com/en/quote/HEPA.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/HEPA.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/HEPA.US.md)
---

# Hepion Pharmaceuticals, Inc. (HEPA.US)

## Company Overview

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hepatocellular carcinoma (HCC), metabolic liver diseases, and chronic liver diseases in the United States. It developed Rencofilstat, a therapeutic drug candidate that binds and inhibits the function of a specific class of isomerase enzymes called cyclophilins that regulates protein folding, as well as preclinical experiments of Rencofilstat reflects decreased liver fibrosis; liver inflammation; liver tumor burden; and titers of HBV, HCV, and HDV. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [epionpharma.com](https://epionpharma.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.07 | 65 | - | - | - |
| PB | 0.57 | 22 | 0.48 | 0.38 | 0.30 |
| Dividend Yield | 0.00% | - | - | - | - |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/HEPA.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/HEPA.US/norm.md)
- [Related News](https://longbridge.com/en/quote/HEPA.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/HEPA.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**